ATE249838T1 - Konserviertes motiv der hepatitis c virus e2/ns1 region - Google Patents

Konserviertes motiv der hepatitis c virus e2/ns1 region

Info

Publication number
ATE249838T1
ATE249838T1 AT94915985T AT94915985T ATE249838T1 AT E249838 T1 ATE249838 T1 AT E249838T1 AT 94915985 T AT94915985 T AT 94915985T AT 94915985 T AT94915985 T AT 94915985T AT E249838 T1 ATE249838 T1 AT E249838T1
Authority
AT
Austria
Prior art keywords
motif
region
virus
hcv
hepatitis
Prior art date
Application number
AT94915985T
Other languages
German (de)
English (en)
Inventor
Amy J Weiner
Michael Houghton
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22037528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE249838(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE249838T1 publication Critical patent/ATE249838T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT94915985T 1993-05-12 1994-05-03 Konserviertes motiv der hepatitis c virus e2/ns1 region ATE249838T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6169993A 1993-05-12 1993-05-12
PCT/US1994/004853 WO1994026306A1 (en) 1993-05-12 1994-05-03 Conserved motif of hepatitis c virus e2/ns1 region

Publications (1)

Publication Number Publication Date
ATE249838T1 true ATE249838T1 (de) 2003-10-15

Family

ID=22037528

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94915985T ATE249838T1 (de) 1993-05-12 1994-05-03 Konserviertes motiv der hepatitis c virus e2/ns1 region

Country Status (7)

Country Link
US (6) US6692907B1 (cg-RX-API-DMAC7.html)
EP (2) EP0697888B1 (cg-RX-API-DMAC7.html)
JP (3) JPH08510240A (cg-RX-API-DMAC7.html)
AT (1) ATE249838T1 (cg-RX-API-DMAC7.html)
CA (1) CA2162557C (cg-RX-API-DMAC7.html)
DE (1) DE69433160T2 (cg-RX-API-DMAC7.html)
WO (1) WO1994026306A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0697888B1 (en) * 1993-05-12 2003-09-17 Chiron Corporation Conserved motif of hepatitis c virus e2/ns1 region
DE19504302A1 (de) * 1995-02-09 1996-08-14 Boehringer Mannheim Gmbh Methode zur serologischen Typisierung mittels typspezifischer Antigene
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
KR970065713A (ko) * 1996-03-19 1997-10-13 성재갑 C형 간염 바이러스(일본형)의 분비형 외피 단백질 1 및 2
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
WO2001021807A1 (en) * 1999-09-23 2001-03-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
DE60039715D1 (de) * 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
WO2001058459A1 (fr) * 2000-02-14 2001-08-16 Mitsubishi Pharma Corporation Remedes contre l'hepatite c
WO2009021063A2 (en) * 2007-08-06 2009-02-12 The Regents Of The University Of California Composition and method of use for hcv immunization
US8314371B2 (en) 2008-11-06 2012-11-20 Applied Materials, Inc. Rapid thermal processing chamber with micro-positioning system
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146633A (en) 1973-05-07 2000-11-14 The Ohio State University Method for treatment of antigenically modified polypeptides
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
EP0043272B1 (en) 1980-07-01 1984-06-13 National Research Development Corporation Production of viral antigens
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0480480A3 (en) 1984-05-11 1992-06-10 Chiron Corporation Enhanced yeast transcription employing hybrid promoter region constructs
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
WO1989004669A1 (en) 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
US5252459A (en) 1988-09-23 1993-10-12 Abbott Laboratories Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
HUT54896A (en) * 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
WO1990014436A1 (en) 1989-05-18 1990-11-29 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5308750A (en) 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
DE69131882T3 (de) * 1990-11-08 2007-05-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Asiloglycoproteine des hepatitis c-virus
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
KR0185426B1 (ko) 1991-06-24 1999-04-01 로버트 피. 블랙버언 씨형 간염 바이러스 폴리펩티드
DK0608261T3 (da) 1991-09-13 2003-03-17 Chiron Corp Sammensætninger med immunreaktivt hepatitis C virus polypeptid
DE69326979T2 (de) 1992-02-05 2000-04-20 Daikin Industries, Ltd. Polytetrafluoräthylenformpulver
ES2287969T3 (es) 1992-03-06 2007-12-16 Innogenetics N.V. Peptidos de vih.
EP0697888B1 (en) * 1993-05-12 2003-09-17 Chiron Corporation Conserved motif of hepatitis c virus e2/ns1 region
ES2197170T3 (es) 1993-11-04 2004-01-01 Innogenetics N.V. Epitopos de celulas t humanas inmunologicamente dominantes del virus de la hepatitis c.
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
BRPI0111731C1 (pt) * 2000-06-15 2021-07-27 Chiron Corp suporte sólido de imunoensaio, métodos de detecção de infecção pelo vírus da hepatite c (hcv) em uma amostra biológica, e de produção de um suporte sólido de imunoensaio, e, kit de teste de imunodiagnóstico

Also Published As

Publication number Publication date
US7252827B1 (en) 2007-08-07
US20030017156A1 (en) 2003-01-23
US7098303B1 (en) 2006-08-29
US6692907B1 (en) 2004-02-17
JP2005097319A (ja) 2005-04-14
EP0697888B1 (en) 2003-09-17
DE69433160D1 (de) 2003-10-30
US7371386B2 (en) 2008-05-13
CA2162557A1 (en) 1994-11-24
EP1421951A3 (en) 2005-10-05
CA2162557C (en) 2004-09-28
US20070014813A1 (en) 2007-01-18
JP2005325126A (ja) 2005-11-24
DE69433160T2 (de) 2004-07-08
JPH08510240A (ja) 1996-10-29
WO1994026306A1 (en) 1994-11-24
EP0697888A1 (en) 1996-02-28
US7135185B1 (en) 2006-11-14
EP1421951A2 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
DE69433160D1 (de) Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
ATE236981T1 (de) Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
DE69334357D1 (de) Nachweis und Typisierung das Hepatitis C Virus (HCV) mittels 5'UTR und NS5 Nukleinsäuresequenzen
AU3844095A (en) New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
FI946066A0 (fi) Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina
CA2032381A1 (en) Viral agent
ATE224956T1 (de) Verfahren zur verstärkten expression von virusproteinen
LU91394I2 (fr) "La protéine L1 recombinante du papillomavirus humain de type 16"-Cervarix
CA2107672A1 (en) Peptides and mixtures thereof for detecting antibodies to hepatitis c virus (hcv)
GR3023664T3 (en) Synthetic antigens for the detection of antibodies to hepatitis C virus.
HK38293A (en) Hepatitis c virus
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
EP0342860A3 (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
ATE115964T1 (de) Non-a non-b sequenzen.
SE1077068T5 (sv) Anvaendning av interferon-alfa-5 vid behandling av virus-hepatopatier
DK257887A (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
FI981381L (fi) Menetelmä HCV-polypeptidien valmistamiseksi
IT1270941B (it) Peptidi di hcv e loro usi.
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus
MXPA94003453A (es) Metodo y composicion para el tratamiento de pacientes con hepatitis b que tienen descompensacion hepatica.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0697888

Country of ref document: EP

RZN Patent revoked